Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01101 ...
Drug Name Capecitabine
Molecular Weight 359.3501
Molecular Formula C15H22FN3O6
CAS Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
External Links
DRUGBANK DB01101
T3DB T3D3507
PubChem Compound 60953
PDR 2039
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 0.4 - 0.4 - DRUGBANK
Melting Point 115.5 ℃ 110-121 ℃ DRUGBANK
Water Solubility 26000.0 mg/L 26 mg/ml DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 70.0 % ~70 % PO, oral; DRUGBANK
C Max 6600.0 ng/ml 6.6±6.0 mcg/ml PO, oral; The Pharmacological Basis of Therapeutics
C Max 470.0 ng/ml 0.47±0.47 mcg/ml PO, oral; Components; The Pharmacological Basis of Therapeutics
T Max 0.50 h 0.5(0.5-1) h PO, oral; The Pharmacological Basis of Therapeutics
T Max 0.50 h 0.5(0.5-2.1) h PO, oral; Components; The Pharmacological Basis of Therapeutics
Clearance 145.0 h/m2 145.0 h/m2 apparent clearance; tumor; Male, men;  Female, women; hepatopathy，LD ↓ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 270.0 L/m2 270.0 L/m2 Steady state volume of distribution; tumor; Male, men;  Female, women; The Pharmacological Basis of Therapeutics
Half-life 0.88 h 45-60 min DRUGBANK
Half-life 0.88 h 45-60 min Metabolite; DRUGBANK
Half-life 1.3 h 1.3 h Male, men;  Female, women; tumor; patients; The Pharmacological Basis of Therapeutics
Half-life 0.72 h 0.72 h Male, men;  Female, women; tumor; patients; The Pharmacological Basis of Therapeutics
Eliminate Route 95.5 % 95.5 % Urinary excretion; DRUGBANK
Eliminate Route 2.6 % 2.6 % Faeces excretion; DRUGBANK
Eliminate Route 3.0 % ~3 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 3.0 % 3 % Urinary excretion; tumor; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 60.0 % <60 % DRUGBANK
Protein Binding 60.0 % <60 % tumor; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adults 2500.0 mg/m2/day 2500 mg/m2/day PO, oral; on days 1 to 14 Xeloda capecitabine PDR
Max dose for adults 1250.0 mg/m2 1250 mg/m2 PO, oral; on days 1 to 14 Xeloda capecitabine PDR
Max dose for geriatric 2500.0 mg/m2/day 2500 mg/m2/day PO, oral; on days 1 to 14 Xeloda capecitabine PDR
Max dose for geriatric 1250.0 mg/m2 1250 mg/m2 PO, oral; on days 1 to 14 Xeloda capecitabine PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1